Codex_V5

Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial.

Pubmed_id: 24273181
Journal: The Journal of infectious diseases
Genbank_id: No known Genbank_id
Date: Apr 2014
Volume: 209
Issue: 8
Pages: 1219-26
Author(s): Chou S, Boivin G, Ives J, Elston R,

Abstract: Newly phenotyped UL54 sequence variants did not significantly change the reported incidence of drug resistance in the clinical trial. Unrecognized sequence variants in diagnostic genotyping reports should be confirmed by additional testing in order to improve clinical decision making.

Mutations:

Mutant	Gene	Virus	Antiviral	EC50 ratio	Phenotype
Q229K	UL54	Human betaherpesvirus 5	Ganciclovir	1.20	No resistance
Q229K	UL54	Human betaherpesvirus 5	Cidofovir	1.00	No resistance
Q229K	UL54	Human betaherpesvirus 5	Foscarnet	1.20	No resistance
E235G	UL54	Human betaherpesvirus 5			Non-viable
D247N	UL54	Human betaherpesvirus 5	Ganciclovir	0.90	No resistance
D247N	UL54	Human betaherpesvirus 5	Cidofovir	0.90	No resistance
D247N	UL54	Human betaherpesvirus 5	Foscarnet	1.30	No resistance
D262N	UL54	Human betaherpesvirus 5	Ganciclovir	1.10	No resistance
D262N	UL54	Human betaherpesvirus 5	Cidofovir	1.00	No resistance
D262N	UL54	Human betaherpesvirus 5	Foscarnet	1.20	No resistance
A269V	UL54	Human betaherpesvirus 5			Natural polymorphism
D271A	UL54	Human betaherpesvirus 5	Ganciclovir	1.20	No resistance
D271A	UL54	Human betaherpesvirus 5	Cidofovir	1.10	No resistance
D271A	UL54	Human betaherpesvirus 5	Foscarnet	1.20	No resistance
D284E	UL54	Human betaherpesvirus 5	Foscarnet	1.20	No resistance
D288N	UL54	Human betaherpesvirus 5	Ganciclovir	1.20	No resistance
D288N	UL54	Human betaherpesvirus 5	Cidofovir	1.20	No resistance
D288N	UL54	Human betaherpesvirus 5	Foscarnet	1.20	No resistance
A336T	UL54	Human betaherpesvirus 5			Natural polymorphism
I341T	UL54	Human betaherpesvirus 5			Natural polymorphism
N345S	UL54	Human betaherpesvirus 5
P375L	UL54	Human betaherpesvirus 5			Natural polymorphism
Y380C	UL54	Human betaherpesvirus 5			Non-viable
L394F	UL54	Human betaherpesvirus 5			Natural polymorphism
F396L	UL54	Human betaherpesvirus 5	Ganciclovir	1.40	No resistance
F396L	UL54	Human betaherpesvirus 5	Cidofovir	1.50	No resistance
F396L	UL54	Human betaherpesvirus 5	Foscarnet	0.90	No resistance
L424V	UL54	Human betaherpesvirus 5	Ganciclovir	1.30	No resistance
L424V	UL54	Human betaherpesvirus 5	Cidofovir	1.30	No resistance
L424V	UL54	Human betaherpesvirus 5	Foscarnet	1.20	No resistance
K426R	UL54	Human betaherpesvirus 5			Natural polymorphism
V450G	UL54	Human betaherpesvirus 5			Natural polymorphism
F460L	UL54	Human betaherpesvirus 5	Ganciclovir	1.20	No resistance
F460L	UL54	Human betaherpesvirus 5	Cidofovir	1.20	No resistance
F460L	UL54	Human betaherpesvirus 5	Foscarnet	1.20	No resistance
H465Y	UL54	Human betaherpesvirus 5			Natural polymorphism
A473V	UL54	Human betaherpesvirus 5			Natural polymorphism
V476G	UL54	Human betaherpesvirus 5	Ganciclovir	0.80	No resistance
V476G	UL54	Human betaherpesvirus 5	Cidofovir	0.90	No resistance
V476G	UL54	Human betaherpesvirus 5	Foscarnet	0.40	Possible hypersensitivity, no resistance
V482G	UL54	Human betaherpesvirus 5			Non-viable
V483A	UL54	Human betaherpesvirus 5			Natural polymorphism
A505V	UL54	Human betaherpesvirus 5	Ganciclovir	1.80	No resistance
A505V	UL54	Human betaherpesvirus 5	Cidofovir	2.00	Low level resistance
A505V	UL54	Human betaherpesvirus 5	Foscarnet	1.10	No resistance
A543S	UL54	Human betaherpesvirus 5	Ganciclovir	1.00	No resistance
A543S	UL54	Human betaherpesvirus 5	Cidofovir	1.00	No resistance
A543S	UL54	Human betaherpesvirus 5	Foscarnet	1.00	No resistance
R581H	UL54	Human betaherpesvirus 5			Non-viable
P617S	UL54	Human betaherpesvirus 5			Natural polymorphism
P628A	UL54	Human betaherpesvirus 5			Natural polymorphism
V634A	UL54	Human betaherpesvirus 5			Natural polymorphism
S651E	UL54	Human betaherpesvirus 5			Natural polymorphism
G653S	UL54	Human betaherpesvirus 5			Natural polymorphism
V654G	UL54	Human betaherpesvirus 5	Ganciclovir	1.10	No resistance
V654G	UL54	Human betaherpesvirus 5	Cidofovir	1.10	No resistance
V654G	UL54	Human betaherpesvirus 5	Foscarnet	1.10	No resistance
S660G	UL54	Human betaherpesvirus 5	Ganciclovir	1.00	No resistance
S660G	UL54	Human betaherpesvirus 5	Cidofovir	0.90	No resistance
S660G	UL54	Human betaherpesvirus 5	Foscarnet	1.10	No resistance
S660N	UL54	Human betaherpesvirus 5			Natural polymorphism
G667N	UL54	Human betaherpesvirus 5	Ganciclovir	0.90	No resistance
G667N	UL54	Human betaherpesvirus 5	Cidofovir	0.80	No resistance
G667N	UL54	Human betaherpesvirus 5	Foscarnet	1.00	No resistance
T691A	UL54	Human betaherpesvirus 5			Natural polymorphism
T691S	UL54	Human betaherpesvirus 5			Natural polymorphism
A692G	UL54	Human betaherpesvirus 5	Ganciclovir	0.80	No resistance
A692G	UL54	Human betaherpesvirus 5	Cidofovir	0.90	No resistance
A692G	UL54	Human betaherpesvirus 5	Foscarnet	1.00	No resistance
A692V	UL54	Human betaherpesvirus 5			Natural polymorphism
A692S	UL54	Human betaherpesvirus 5			Natural polymorphism
F718L	UL54	Human betaherpesvirus 5			Non-viable
F718S	UL54	Human betaherpesvirus 5			Non-viable
I726T	UL54	Human betaherpesvirus 5	Ganciclovir	2.00	Low level resistance
I726T	UL54	Human betaherpesvirus 5	Cidofovir	1.70	No resistance
I726T	UL54	Human betaherpesvirus 5	Foscarnet	1.10	No resistance
I726V	UL54	Human betaherpesvirus 5	Ganciclovir	1.90	No resistance
I726V	UL54	Human betaherpesvirus 5	Cidofovir	1.90	No resistance
I726V	UL54	Human betaherpesvirus 5	Foscarnet	1.20	No resistance
E793V	UL54	Human betaherpesvirus 5	Ganciclovir	0.90	No resistance
E793V	UL54	Human betaherpesvirus 5	Cidofovir	0.70	No resistance
E793V	UL54	Human betaherpesvirus 5	Foscarnet	1.10	No resistance
Q795P	UL54	Human betaherpesvirus 5	Ganciclovir	0.90	No resistance
Q795P	UL54	Human betaherpesvirus 5	Cidofovir	0.90	No resistance
Q795P	UL54	Human betaherpesvirus 5	Foscarnet	1.10	No resistance
Q795R	UL54	Human betaherpesvirus 5	Ganciclovir	1.00	No resistance
Q795R	UL54	Human betaherpesvirus 5	Cidofovir	0.90	No resistance
Q795R	UL54	Human betaherpesvirus 5	Foscarnet	0.90	No resistance
R800C	UL54	Human betaherpesvirus 5			Natural polymorphism
G822D	UL54	Human betaherpesvirus 5			Non-viable
M828V	UL54	Human betaherpesvirus 5			Non-viable
G841S	UL54	Human betaherpesvirus 5	Ganciclovir	2.20	Low level resistance
G841S	UL54	Human betaherpesvirus 5	Cidofovir	1.10	No resistance
G841S	UL54	Human betaherpesvirus 5	Foscarnet	2.10	Low level resistance
R847H	UL54	Human betaherpesvirus 5			Natural polymorphism
N855D	UL54	Human betaherpesvirus 5			Natural polymorphism
P859A	UL54	Human betaherpesvirus 5	Ganciclovir	0.80	No resistance
P859A	UL54	Human betaherpesvirus 5	Cidofovir	1.00	No resistance
P859A	UL54	Human betaherpesvirus 5	Foscarnet	0.80	No resistance
H863R	UL54	Human betaherpesvirus 5			Natural polymorphism
L890F	UL54	Human betaherpesvirus 5			Natural polymorphism
T892I	UL54	Human betaherpesvirus 5			Natural polymorphism
V902G	UL54	Human betaherpesvirus 5	Ganciclovir	1.20	No resistance
V902G	UL54	Human betaherpesvirus 5	Cidofovir	1.00	No resistance
V902G	UL54	Human betaherpesvirus 5	Foscarnet	1.00	No resistance
E903G	UL54	Human betaherpesvirus 5			Natural polymorphism
G920S	UL54	Human betaherpesvirus 5			Natural polymorphism
V927M	UL54	Human betaherpesvirus 5			Natural polymorphism
K947E	UL54	Human betaherpesvirus 5	Ganciclovir	1.00	No resistance
K947E	UL54	Human betaherpesvirus 5	Cidofovir	1.00	No resistance
K947E	UL54	Human betaherpesvirus 5	Foscarnet	1.10	No resistance
M959T	UL54	Human betaherpesvirus 5	Ganciclovir	1.20	No resistance
M959T	UL54	Human betaherpesvirus 5	Cidofovir	0.90	No resistance
M959T	UL54	Human betaherpesvirus 5	Foscarnet	1.20	No resistance
A972V	UL54	Human betaherpesvirus 5			Natural polymorphism
S1000L	UL54	Human betaherpesvirus 5			Natural polymorphism
D1005N	UL54	Human betaherpesvirus 5			Natural polymorphism
R1006C	UL54	Human betaherpesvirus 5			Natural polymorphism

CHARMD

Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database

Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial.

Mutations: